The present invention is directed to a nucleic acid suitable for use in treatment or prophylaxis of an infection with a coronavirus, preferably with a Coronavirus SARS-CoV-2, or a disorder related to such an infection, preferably COVID-19. The present invention is also directed to compositions, polypeptides, and vaccines. The compositions and vaccines preferably comprise at least one of said nucleic acid sequences, preferably nucleic acid sequences in association a lipid nanoparticle (LNP). The invention is also directed to first and second medical uses of the nucleic acid, the composition, the polypeptide, the combination, the vaccine, and the kit, and to methods of treating or preventing a coronavirus infection, preferably a Coronavirus infection.

The present invention is directed to a nucleic acid suitable for use in treatment or prophylaxis of an infection with a coronavirus, preferably with a Coronavirus SARS-CoV-2, or a disorder related to such an infection, preferably COVID-19. The present invention is also directed to compositions, polypeptides, and vaccines. The compositions and vaccines preferably comprise at least one of said nucleic acid sequences, preferably nucleic acid sequences in association a lipid nanoparticle (LNP). The invention is also directed to first and second medical uses of the nucleic acid, the composition, the polypeptide, the combination, the vaccine, and the kit, and to methods of treating or preventing a coronavirus infection, preferably a Coronavirus infection.

Described herein are CpG-adjuvanted SARS-CoV-2 vaccines and compositions and methods of producing and administering said vaccines to subjects in need thereof.

Described herein are CpG-adjuvanted SARS-CoV-2 vaccines and compositions and methods of producing and administering said vaccines to subjects in need thereof.

Computational prediction of immunogenic epitopes is a promising platform for designing therapeutic and preventive vaccines. A potential target is, for example, the human immunodeficiency virus (HIV-1) for which, despite decades of efforts, no vaccine is available. Indeed, due to the enormous variability of the virus, a single formulation effective against all or most HIV strains might not be achievable. Moreover, upon infecting host cells, HIV-1 can integrate in the host genome and form long lasting latent reservoirs that are not susceptible to common antiretroviral treatments. Therefore, a therapeutic vaccine designed to eliminate infected cells might represent a key component of strategies aimed at curing the infection. We herein introduce an automated algorithm to produce personalized and population-based vaccines.

Computational prediction of immunogenic epitopes is a promising platform for designing therapeutic and preventive vaccines. A potential target is, for example, the human immunodeficiency virus (HIV-1) for which, despite decades of efforts, no vaccine is available. Indeed, due to the enormous variability of the virus, a single formulation effective against all or most HIV strains might not be achievable. Moreover, upon infecting host cells, HIV-1 can integrate in the host genome and form long lasting latent reservoirs that are not susceptible to common antiretroviral treatments. Therefore, a therapeutic vaccine designed to eliminate infected cells might represent a key component of strategies aimed at curing the infection. We herein introduce an automated algorithm to produce personalized and population-based vaccines.

Compositions for use as a vaccine against SARS-CoV-2 infection are disclosed, which comprise either a polypeptide that comprises at least one surge-associated mutation (e.g., deletion) in its amino acid sequence or a nucleic acid (e.g., mRNA) that encodes said polypeptide. Also disclosed are formulations that include these compositions, antibodies or their antigen-biding fragments directed to these polypeptides, methods of making such antibodies, methods of vaccinating subjects against SARS-CoV-2 infection, and methods of selecting an antibody, convalescent plasma, or vaccine against SARS-CoV-2 infection.

Compositions for use as a vaccine against SARS-CoV-2 infection are disclosed, which comprise either a polypeptide that comprises at least one surge-associated mutation (e.g., deletion) in its amino acid sequence or a nucleic acid (e.g., mRNA) that encodes said polypeptide. Also disclosed are formulations that include these compositions, antibodies or their antigen-biding fragments directed to these polypeptides, methods of making such antibodies, methods of vaccinating subjects against SARS-CoV-2 infection, and methods of selecting an antibody, convalescent plasma, or vaccine against SARS-CoV-2 infection.

The present disclosure is directed to compositions and methods useful for treating, as well as vaccinating against, SARS-CoV-2 viral infections, including SARS-CoV-2 variant viral infections.

The present disclosure is directed to compositions and methods useful for treating, as well as vaccinating against, SARS-CoV-2 viral infections, including SARS-CoV-2 variant viral infections.